The estimated Net Worth of Life Sciences Viii, L.P.Fhm... is at least $92.2 Million dollars as of 24 October 2023. Life Fhm owns over 80,000 units of Arcutis Biotherapeutics Inc stock worth over $92,199,721 and over the last 2 years Life sold ARQT stock worth over $0.
Life has made over 2 trades of the Arcutis Biotherapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Life bought 80,000 units of ARQT stock worth $200,000 on 24 October 2023.
The largest trade Life's ever made was buying 250,000 units of Arcutis Biotherapeutics Inc stock on 5 August 2022 worth over $5,000,000. On average, Life trades about 165,000 units every 223 days since 2022. As of 24 October 2023 Life still owns at least 8,764,232 units of Arcutis Biotherapeutics Inc stock.
You can see the complete history of Life Fhm stock trades at the bottom of the page.
Over the last 5 years, insiders at Arcutis Biotherapeutics Inc have traded over $33,184,604 worth of Arcutis Biotherapeutics Inc stock and bought 3,754,945 units worth $71,202,175 . The most active insiders traders include Jonathan Silverstein, Patrick J Heron und Advisors Llcorbimed Capital.... On average, Arcutis Biotherapeutics Inc executives and independent directors trade stock every 10 days with the average trade being worth of $361,425. The most recent stock trade was executed by Howard G. Welgus on 3 September 2024, trading 10,000 units of ARQT stock currently worth $107,700.
arcutis biotherapeutics, inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. its lead product candidate is arq-151, a topical cream formulation of roflumilast that is in phase iii clinical trials for the treatment of plaque psoriasis and atopic dermatitis. the company is also developing arq-154, a topical foam formulation of arq-151 for the treatment of seborrheic dermatitis and scalp psoriasis; arq-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and arq-255, a topical formulation of arq-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. the company was formerly known as arcutis, inc. and changed its name to arcutis biotherapeutics, inc. in october 2019. arcutis biotherapeutics, inc. was founded in 2016 and is headquartered in westlake village, california.
Arcutis Biotherapeutics Inc executives and other stock owners filed with the SEC include: